-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Venlafaxine in the treatment of panic disorder
(2380) Views (435) Full article downloads
Authors: Martin A Katzman, Leslie Jacobs
Published Date May 2007
Volume 2007:3(1) Pages 59 - 67
DOI: http://dx.doi.org/10.2147/NDT.S
Martin A Katzman1,2,3, Leslie Jacobs1
1START Clinic for the Mood and Anxiety Disorders, Toronto, ON, Canada; 2University of Toronto, ON, Canada; 3Northern Ontario School of Medicine, Toronto, ON, Canada
Abstract: Venlafaxine XR is a novel, dual acting SNRI antidepressant, which inhibits both serotonin and norepinephrine reuptake. Controlled trials have demonstrated the efficacy and safety of venlafaxine in the treatment of panic disorder. Generally well tolerated, with side effects that usually abate with continued treatment, venlafaxine is an important option to the SSRIs for the treatment of patients with panic disorder.
Keywords: anxiety disorders, panic disorder, antidepressant therapy, remission, venlafaxine, selective serotonin norepinephrine reuptake inhibitor
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference
- Moderate alcohol consumption and cognitive risk




